CDI Labs

13/08/2025

In a recent paper published in Frontiers in Immunology, Dr. Ying Ye and colleagues at the Chongqing Medical University revealed down-regulated autoantibodies in early lung cancer patients. These tumor-associated autoantibodies can be detected months to years before diagnosis, offering a promising avenue for earlier detection. Using large-scale screening with , researchers identified 15 decreased autoantibodies that provide 80% sensitivity and 87% specificity for stage IA lung cancer. Notably, 10 of these autoantibodies returned to normal levels post-surgery, indicating their potential as biomarkers for residual tumors.

Read blog here,
https://www.cdilabs.com/blogs/down-regulated-autoantibodies-in-early-lung-cancer-patients

View / download paper here,
https://www.cdilabs.com/content/publications/pub-exploration-of-the-diagnostic-and-prognostic-roles-ye

View paper in Frontiers in Immunology,
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1538071/full

12/08/2025

Next week, we're in beautiful Vienna, Austria, for the conference! Join us at Booth 64 to discover how CDI Labs is revolutionizing immunology research with our cutting-edge technologies and unparalleled lab services. We're dedicated to advancing research in immunology, helping scientists unlock new insights into immune responses and disorders. Don’t miss the chance to connect with our experts and explore innovative solutions that empower your research in autoimmune diseases and beyond.

More info here,
https://iuis2025.org/

08/08/2025

We’re excited to celebrate (and maybe brag a little) about our impact on advancing research and empowering scientists to publish their groundbreaking studies in some of the world's most prestigious journals. With over 350+ high-profile papers citing our cutting-edge platforms and lab services, we're proud to contribute to a diverse range of transformative scientific research that's reshaping our understanding of autoantibodies, biomarkers, and target identification across disease research, drug development, and therapeutics.

This extensive body of work represents more than citations, it reflects our commitment to advancing scientific discovery and empowering researchers to push the boundaries of what's possible. From novel therapeutic targets to innovative diagnostic approaches, the research enabled by our platforms continues to reshape the landscape of autoimmune research and precision medicine.

Be sure to check out our user-friendly Publications Portal, where you can effortlessly explore a wealth of articles, authors, and institutions. Delve into the impressive body of work generated by our vibrant community and witness the significant impact of our customers' research. Visit our portal today to discover the depth of innovation that defines CDI Labs!

Publications Portal here,
https://www.cdilabs.com/resources/publications

07/08/2025

Autoantibodies have long been associated solely with autoimmune disease, but that may be changing.
In a recent talk hosted by Tyler Hulett, Chief Scientific Officer CDI Labs, he shared insights that are reshaping our understanding of these powerful immune markers. Far from being rare, autoantibodies are common, complex, and individually unique acting as both storytellers of past exposures and drivers of future disease.
Discover how advances in proteome-array technology and deep immune-profiling are unlocking new diagnostics, biomarkers, and therapeutic pathways in chronic illness and precision medicine.
Looking to explore your own immune fingerprint? Connect with us at [email protected]. Read full blog below.

Autoantibodies have long been associated solely with autoimmune disease, but that may be changing. In a recent talk hosted by Tyler Hulett, Chief Scientific Officer CDI Labs, he shared insights that are reshaping our understanding of these powerful immune markers. Far from being rare, autoantibodies...

31/07/2025

Melanoma remains a critical global health issue, but scientific innovation is opening new doors for early diagnosis and improved patient outcomes.

Did you know your immune system could help detect melanoma even before symptoms appear? Autoantibodies specialized proteins produced in response to cancer are emerging as promising, non-invasive biomarkers for cancer detection and monitoring.

Our latest blog unpacks their pivotal role in melanoma and highlights how advanced technologies are bringing us closer to reliable, blood-based diagnostic solutions.

Read full article here: https://tinyurl.com/4hu74f7s

30/07/2025

PRESS RELEASE: We’re excited to announce the launch of our comprehensive Pan-isotype Profiling and Analysis platform! This cutting-edge solution enables researchers to explore all isotypes and subclasses, including IgA, IgD, IgE, IgG, and IgM, providing deeper insights into immune responses. With our advanced ™ and ® platforms, you can now conduct thorough pan-isotype profiling across thousands of human proteins. Whether you're investigating inflammatory conditions, autoimmune responses, or overall immune state, our innovative approach allows for a comprehensive and detailed analysis.

Dr. Barney Saunders states,"In the past, autoantibody discovery and profiling has often been limited to pan-IgG analysis, but each isotype and subclass plays a distinct role in humoral immunity... While earlier limitations in technology made this difficult, our new pan-isotype and subclass analysis capabilities now make it possible to explore these differences in far greater depth."

Learn more about Pan-isotype Profiling here:
https://cdilabs.com/services/pan-isotype-profiling

Read press release here:
https://cdilabs.com/news-events/cdi-labs-launches-pan-isotype-analysis

16/07/2025

Decode murine autoantibodies like never before – profile over 50,000+ proteins from the entire mouse proteome in ONE assay. Our ™ PhIP-Seq (Phage Display ImmunoPrecipitation Sequencing) platform enables researchers to uncover epitope-level insights into immune responses, autoimmune disease mechanisms, and novel therapeutic targets with unmatched precision. Explore the incredible potential of murine models in advancing biomedical research and innovative therapies.

MouseScan PhIP-Seq Advantages:

✔ Simultaneously profiles over 50,000+ proteins and isoforms from the entire GRCm38.p5 mouse proteome
✔ Uses overlapping 62-mer peptide tiles displayed on bacteriophages; detects antibodies against virtually any mouse antigen with pinpoint accuracy
✔ Transforms weeks of tedious assays into one comprehensive test

Learn more here,
https://www.cdilabs.ca/products/mousescan-phip-seq

15/07/2025

In a paper published in Frontiers in Immunology, Lixin Zhang and colleagues at the University of Pittsburgh School of Medicine explore the complex role of B lymphocytes in the ovarian tumor microenvironment. Utilizing our cutting-edge human proteome microarray, the researchers profiled over 21,000 proteins to identify critical antigens recognized by antibody-secreting B cells in cases of epithelial ovarian cancer (EOC). Notably, they found anti-CCDC155 circulating IgG antibodies in a substantial proportion of EOC patients’ sera, suggesting potential biomarkers for patient prognosis. This collaboration between HuProt technology and ovarian cancer research paves the way for future investigations into B cell biology, target antigen recognition, and the role of Epstein-Barr virus (EBV) proteins in shaping the tumor microenvironment.

View / download paper here,
https://www.cdilabs.com/content/publications/pos-characterization-of-latently-infected-ebv-antibody-secreting-b-cells-zhang

09/07/2025

PRESS RELEASE: We are thrilled to announce the launch of our innovative Peptide Hormone PhIP-Seq library, a groundbreaking advancement in identifying hormone-specific autoantibodies. This cutting-edge technology combines phage display with next-gen sequencing, enabling high-throughput screening and detailed epitope mapping of autoantibody responses against a diverse panel of human peptide hormones. Understanding the role of these autoantibodies is crucial in unveiling the complexities of hormonal dysregulation and its connection to diseases like obesity, diabetes, and various mood disorders. Our comprehensive library allows researchers to explore the immunological aspects of endocrine function in new and profound ways.

"Our new Peptide Hormone Library provides researchers with a cost-effective and high-throughput tool to interrogate these autoantibody responses," says CEO Dr. Barney Saunders.

More info here,
https://www.cdilabs.ca/services/peptide-hormone-phip-seq

Press release here,
https://www.cdilabs.com/news-events/cdi-labs-canada-launches-peptide-hormone-phip-seq

07/07/2025

In this insightful blog by Shaohui Hu, Wendy Yap and Shuang Liu, we explore the history and innovation of ™, the world’s largest, most comprehensive protein microarray. Representing over 81% of the human proteome, HuProt revolutionizes the study of protein functions and interactions with the broadest coverage and accuracy. Developed by Heng Zhu’s team at Johns Hopkins University in 2009, HuProt builds on decades of advancements in proteomics and enables breakthroughs in biomarker discovery, disease research, and drug development. Furthermore, HuProt is complemented by cutting-edge technologies like ® PhIP-Seq for epitope analysis and ® for antibody profiling. See how CDI Labs is driving proteomics innovation forward.

View blog here,
https://www.cdilabs.com/blogs/unlocking-the-secrets-of-the-human-proteome

01/07/2025

Unlock the secrets of the human immune system with ® PHIP-Seq, the cutting-edge platform revolutionizing pathogen detection and immune profiling. Powered by Phage Display ImmunoPrecipitation Sequencing (PHIP-Seq), VirScan takes immune analysis to the next level. By uncovering antibodies generated across an individual's unique history of viral exposures, it provides unparalleled insights into how the immune system has responded to past and present infections.

From decoding the intricate interplay of immunity to transforming disease research and diagnostics, VirScan® PHIP-Seq enables researchers to:

✔ Map an Individual's Viral Exposure
✔ Reveal Immune System Dynamics in Unprecedented Detail
✔ Drive Next-Gen Discoveries in Medicine and Health

Learn more,
https://cdilabs.ca/services/virscan-phip-seq

25/06/2025

CDI Labs at ! Join us tomorrow, June 26, at 7:30 PM (Poster # Th189), for an exciting poster session titled, "Seromic Atlas of APS-1 Syndrome." Presented by Tyler Hulett, PhD, this session will delve into groundbreaking advances in the use of synthetic biology tools for high-throughput serologic antibody profiling. Learn how Phage Display Immunoprecipitation Sequencing (PhIP-Seq) and protein microarray technologies enable massively multiplexed and unbiased investigations into antibody repertoires. Explore how these cutting-edge tools bring new insights into the mechanisms of APS-1 (Autoimmune Polyendocrine Syndrome Type 1) autoimmunity and the diverse antibody landscapes of affected patients.

Where: Poster Hall
When: June 26 at 7:30 PM
Poster #: Th189